Cells : Actualité Cells en direct - P1 | Bourse Reflex
Accueil > Tags > Cells

  • Toutes les actualités en rapport avec « Cells »

02/05 07:30 Cells - ORAL PRESENTATION OF THERANEXUS AT THE 9TH EUROPEAN CONGRESS ON NARCOLEPSY 5 AND 6 MAY IN MONTPELLIER

26/04 18:00 Cells - THERANEXUS ANNOUNCES ITS 2017 ANNUAL RESULTS AND PRESENTS AN UPDATE ON THE PROGRESS OF ITS CLINICAL TRIALS

23/04 07:30 Cells - THN102 OBTAINS INVESTIGATIONAL NEW DRUG STATUS FROM THE FOOD AND DRUG ADMINISTRATION (FDA)

19/04 18:00 Cells - THERANEXUS ANNOUNCES THE FIRST EUROPEAN APPROVAL FOR ITS PHASE 2 CLINICAL TRIAL WITH THN 102 IN PARKINSON'S DISEASE PATIENTS

21/03 07:30 Cells - THERANEXUS ANNOUNCES A SUCCESSFUL CLINICAL PHARMACOKINETIC STUDY AS PART OF THE DEVELOPMENT OF ITS DRUG CANDIDATES THN201 AND THN101

15/03 07:30 Cells - THERANEXUS AND THE COLLEGE DE FRANCE SIGN A RESEARCH AGREEMENT ON ASTROCYTE-NEURON INTERACTIONS

28/09 07:30 Cells - Theranexus files its registration document as part of its planned Initial Public Offering (IPO) on the Euronext Growth market in Paris

14/03 18:00 Cells - Quantum Genomics announces positive data from new preclinical studies with QGC001

13/12 18:30 Cells - GENTICEL REPORTS FINAL RESULTS OF GTL001 PHASE 2 TRIAL IN HPV16/18-INFECTED WOMEN

23/06 17:45 Cells - GENTICEL REPORTS 18 MONTH INTERIM ANALYSIS OF GTL001 PHASE 2 TRIAL IN HPV16/18 INFECTED WOMEN

28/04 18:35 Cells - BUSINESS UPDATE - FIRST QUARTER 2016

20/04 18:30 Cells - GENTICEL REPORTS ADDITIONAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

09/03 17:45 Cells - Stemcis lance une étude clinique chez l'homme pour son dispositif médical de traitement de l'arthrose basé sur les cellules souches adipeuses

27/01 18:40 Cells - GENTICEL REPORTS INITIAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

27/01 18:30 Cells - RÉSULTATS INITIAUX À 12 MOIS DE L'ESSAI DE PHASE 2 DE GTL001, LE CANDIDAT IMMUNOTHÉRAPEUTIQUE HPV DE GENTICEL

20/04 18:40 Cells - Genticel to Present Further Promising Pharmacology In-Vivo Results of its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (ProCervix), at AACR Annual Meeting 2015

01/04 17:00 Cells - 2014 Reference Document Available with Annual Financial Report

06/03 18:00 Cells - Implementation of a Programmed Trading Mandate

02/03 19:00 Cells - 2014 Annual Results

05/02 16:30 Cells - Genticel presents pipeline development in EUROGIN congress held in Seville, Spain - 4 to 7 February 2015